메뉴 건너뛰기




Volumn 7, Issue 2, 2010, Pages 75-81

Hereditary breast and ovarian cancer testing: Integration and outcomes within community oncology practices

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

EID: 77649209488     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70558-7     Document Type: Article
Times cited : (4)

References (28)
  • 1
    • 0028113345 scopus 로고
    • A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
    • Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
    • (1994) Science , vol.266 , pp. 66-71
    • Miki, Y.1    Swensen, J.2    Shattuck-Eidens, D.3
  • 2
    • 0006713602 scopus 로고
    • Identification of the breast cancer susceptibility gene BRCA2
    • Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-792.
    • (1995) Nature , vol.378 , pp. 789-792
    • Wooster, R.1    Bignell, G.2    Lancaster, J.3
  • 3
    • 0037087536 scopus 로고    scopus 로고
    • Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals
    • Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-1490.
    • (2002) J Clin Oncol , vol.20 , pp. 1480-1490
    • Frank, T.S.1    Deffenbaugh, A.M.2    Reid, J.E.3
  • 4
    • 0142178215 scopus 로고    scopus 로고
    • Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2
    • King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302 :643-646.
    • (2003) Science , vol.302 , pp. 643-646
    • King, M.C.1    Marks, J.H.2    Mandell, J.B.3
  • 5
    • 0035098503 scopus 로고    scopus 로고
    • Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer
    • Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-710.
    • (2001) Am J Hum Genet , vol.68 , pp. 700-710
    • Risch, H.A.1    McLaughlin, J.R.2    Cole, D.E.3
  • 6
    • 29144509766 scopus 로고    scopus 로고
    • BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
    • Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-2816.
    • (2005) Cancer , vol.104 , pp. 2807-2816
    • Pal, T.1    Permuth-Wey, J.2    Betts, J.A.3
  • 7
    • 85036791810 scopus 로고    scopus 로고
    • Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with bilateral invasive breast cancer
    • Paper presented at: December 3-6, San Antonio, TX
    • Parlanti AA, Burbidge LA, Shappell HL, et al. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with bilateral invasive breast cancer. Paper presented at: 26th Annual San Antonio Breast Cancer Symposium; December 3-6, 2003; San Antonio, TX.
    • (2003) 26th Annual San Antonio Breast Cancer Symposium
    • Parlanti, A.A.1    Burbidge, L.A.2    Shappell, H.L.3
  • 8
    • 0028843102 scopus 로고
    • Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium
    • Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-271.
    • (1995) Am J Hum Genet , vol.56 , pp. 265-271
    • Easton, D.F.1    Ford, D.2    Bishop, D.T.3
  • 9
    • 0030910022 scopus 로고    scopus 로고
    • The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
    • Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-1408.
    • (1997) N Engl J Med , vol.336 , pp. 1401-1408
    • Struewing, J.P.1    Hartge, P.2    Wacholder, S.3
  • 10
    • 0028330276 scopus 로고
    • Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium
    • Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-695.
    • (1994) Lancet , vol.343 , pp. 692-695
    • Ford, D.1    Easton, D.F.2    Bishop, D.T.3    Narod, S.A.4    Goldgar, D.E.5
  • 11
    • 0038744296 scopus 로고    scopus 로고
    • Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies
    • Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-1130.
    • (2003) Am J Hum Genet , vol.72 , pp. 1117-1130
    • Antoniou, A.1    Pharoah, P.D.2    Narod, S.3
  • 12
    • 33747829208 scopus 로고    scopus 로고
    • Available at:, Accessed February 4, 2010
    • American Cancer Society. Breast Cancer Facts & Figures 2009-2010. Available at: www.cancer.org/docroot/STT/stt-0.asp. Accessed February 4, 2010.
    • Breast Cancer Facts & Figures , pp. 2009-2010
  • 13
    • 0347492085 scopus 로고
    • Horner MJ, Ries LAG, Krapcho M, et al, eds, Bethesda, MD: National Cancer Institute;, 2009
    • Horner MJ, Ries LAG, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
    • (1975) SEER Cancer Statistics Review
  • 15
    • 85036798531 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology-V.1.2009. Genetic/Familial High-Risk Assessment: Breast and Ovarian. 2009. Available at: http://www.nccn.org. Accessed February 4, 2010.
    • National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology-V.1.2009. Genetic/Familial High-Risk Assessment: Breast and Ovarian. 2009. Available at: http://www.nccn.org. Accessed February 4, 2010.
  • 16
    • 33645675556 scopus 로고    scopus 로고
    • Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update
    • Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006;118:2281-2284.
    • (2006) Int J Cancer , vol.118 , pp. 2281-2284
    • Gronwald, J.1    Tung, N.2    Foulkes, W.D.3
  • 17
    • 0032514413 scopus 로고    scopus 로고
    • Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group
    • Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-428.
    • (1998) N Engl J Med , vol.339 , pp. 424-428
    • Narod, S.A.1    Risch, H.2    Moslehi, R.3
  • 18
    • 1842614292 scopus 로고    scopus 로고
    • Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group
    • Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:1055-1062.
    • (2004) J Clin Oncol , vol.22 , pp. 1055-1062
    • Rebbeck, T.R.1    Friebel, T.2    Lynch, H.T.3
  • 19
    • 0037162115 scopus 로고    scopus 로고
    • Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation
    • Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-1615.
    • (2002) N Engl J Med , vol.346 , pp. 1609-1615
    • Kauff, N.D.1    Satagopan, J.M.2    Robson, M.E.3
  • 20
    • 0037162110 scopus 로고    scopus 로고
    • Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations
    • Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-1622.
    • (2002) N Engl J Med , vol.346 , pp. 1616-1622
    • Rebbeck, T.R.1    Lynch, H.T.2    Neuhausen, S.L.3
  • 21
    • 21144436491 scopus 로고    scopus 로고
    • Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families
    • Hendrickson BC, Judkins T, Ward BD, et al. Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families. Genes Chromosomes Cancer 2005;43:309-313.
    • (2005) Genes Chromosomes Cancer , vol.43 , pp. 309-313
    • Hendrickson, B.C.1    Judkins, T.2    Ward, B.D.3
  • 22
    • 0027295745 scopus 로고
    • A suggested nomenclature for designating mutations
    • Beaudet AL, Tsui LC. A suggested nomenclature for designating mutations. Hum Mutat 1993;2:245-248.
    • (1993) Hum Mutat , vol.2 , pp. 245-248
    • Beaudet, A.L.1    Tsui, L.C.2
  • 23
    • 4544374528 scopus 로고    scopus 로고
    • BRCA1 and BRCA2: 1994 and beyond
    • Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-676.
    • (2004) Nat Rev Cancer , vol.4 , pp. 665-676
    • Narod, S.A.1    Foulkes, W.D.2
  • 24
    • 85036778602 scopus 로고    scopus 로고
    • Myriad Genetics Laboratories Inc. The 2008 BRCA1/2 Gene Mutation Prevalence Tables. 2008. Available at: www.myriadtests. com/pdfs/BRCA-Mutation- Prevalence-Percentages.pdf. Accessed February 4, 2010.
    • Myriad Genetics Laboratories Inc. The 2008 BRCA1/2 Gene Mutation Prevalence Tables. 2008. Available at: www.myriadtests. com/pdfs/BRCA-Mutation- Prevalence-Percentages.pdf. Accessed February 4, 2010.
  • 25
    • 0038501057 scopus 로고    scopus 로고
    • genetic testing for cancer susceptibility
    • American Society of Clinical Oncology policy statement update
    • American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397-2406.
    • (2003) J Clin Oncol , vol.21 , pp. 2397-2406
  • 26
    • 65649112508 scopus 로고    scopus 로고
    • BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer
    • Hall MJ, Reid JE, Burbidge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 2009;115:2222-2233.
    • (2009) Cancer , vol.115 , pp. 2222-2233
    • Hall, M.J.1    Reid, J.E.2    Burbidge, L.A.3
  • 27
    • 27244439695 scopus 로고    scopus 로고
    • Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population
    • Dominguez FJ, Jones JL, Zabicki K, et al. Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population. Cancer 2005;104:1849-1853.
    • (2005) Cancer , vol.104 , pp. 1849-1853
    • Dominguez, F.J.1    Jones, J.L.2    Zabicki, K.3
  • 28
    • 0037270101 scopus 로고    scopus 로고
    • Prevalence of family history of breast and ovarian cancer in a single primary care practice using a self-administered questionnaire
    • Hughes KS, Roche C, Campbell CT, et al. Prevalence of family history of breast and ovarian cancer in a single primary care practice using a self-administered questionnaire. Breast J 2003;9:19-25.
    • (2003) Breast J , vol.9 , pp. 19-25
    • Hughes, K.S.1    Roche, C.2    Campbell, C.T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.